NCT05643248View on ClinicalTrials.gov

To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

September 26, 2023

Study Completion Date

September 26, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

NEX-20A

Subcutaneous prolonged-release injection

Trial Locations (1)

Unknown

CTC Clinical Research Consultants AB, Uppsala

Sponsors

Lead Sponsor

Nanexa AB
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

lead

Nanexa AB

INDUSTRY